during hospitalisation, surgery or acute illness), in underweight people or when the diagnosis of type 1 diabetes is suspected
Companies that swiftly identify and respond to these changes will position themselves for success, while those adopting a cautious wait-and-see approach may face declining sales
A pill version of semaglutidethe generic name for Novo Nordisks diabetes drug Ozempic and its weight-loss version Wegovywas approved by the Food and Drug Administration as a type 2 diabetes treatment in 2019, but it has largely flown under the radar
Using a syringe to extract tirzepatide from an injection pen also carries a contamination risk
This limits our ability to determine whether diabetes itself constitutes an independent risk factor for adverse gastrointestinal outcomes with these agents
Joaqui VB, Gmez NB, Ortiz RC, et al